By supporting your lead candidate selection process through a developability assessment where we evaluate the design of your screening studies in terms of safety and efficacy and to identify biopharmaceutical (CMC) hurdles to overcome issues later in development like poor bioavailability.

We believe that the involvement of a toxicologist in designing your in vivo proof of concept studies helps to de-risk your development program early and ensures a smooth transition from the discovery to the development stage.

Get in touch
with our Xpert

François van Och

Managing Partner, Non-Clinical Team Lead